Patents by Inventor Peter J. Houghton

Peter J. Houghton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents
    Patent number: 7879868
    Abstract: The present invention relates to the use of imatinib of the following formula or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a cancer that expresses breast cancer resistant protein (BCRP) in a human subject in need of such a treatment.
    Type: Grant
    Filed: October 10, 2003
    Date of Patent: February 1, 2011
    Assignee: Novartis AG
    Inventors: Peter J. Houghton, Peter Traxler
  • Compositions and methods for sensitizing and inhibiting growth of human tumor cells
    Patent number: 7452717
    Abstract: Polynucleotides encoding carboxylesterase enzymes and polypeptides encoded by the polynucleotides which are capable of metabolizing a chemotherapeutic prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing tumor cells to a prodrug chemotherapeutic agent and inhibiting tumor growth with this enzyme are also provided. In addition, screening assay for identification of drugs activated by this enzyme are described.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: November 18, 2008
    Assignee: St. Jude Children's Research Hospital
    Inventors: Mary K. Danks, Philip M. Potter, Peter J. Houghton
  • Compositions and methods for sensitizing and inhibiting growth of human tumor cells
    Patent number: 7018631
    Abstract: Polynucleotides encoding a carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a chemotherapeutic prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing tumor cells to a prodrug chemotherapeutic agent and inhibiting tumor growth with this enzyme are also provided. In addition, screening assay for identification of drugs activated by this enzyme are described.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: March 28, 2006
    Assignee: St. Jude Children's Research Hospital
    Inventors: Mary K. Danks, Philip M. Potter, Peter J. Houghton
  • Compositions and methods for sensitizing and inhibiting growth of human tumor cells
    Publication number: 20040259829
    Abstract: Polynucleotides encoding carboxylesterase enzymes and polypeptides encoded by the polynucleotides which are capable of metabolizing a chemotherapeutic prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing tumor cells to a prodrug chemotherapeutic agent and inhibiting tumor growth with this enzyme are also provided. In addition, screening assay for identification of drugs activated by this enzyme are described.
    Type: Application
    Filed: June 1, 2004
    Publication date: December 23, 2004
    Inventors: Mary K. Danks, Philip M. Potter, Peter J. Houghton
  • Compositions and methods for sensitizing and inhibiting growth of human tumor cells
    Patent number: 6800483
    Abstract: Polynucleotides encoding carboxylesterase enzymes and polypeptides encoded by the polynucleotides which are capable of metabolizing a chemotherapeutic prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing tumor cells to a prodrug chemotherapeutic agent and inhibiting tumor growth with this enzyme are also provided. In addition, screening assay for identification of drugs activated by this enzyme are described.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: October 5, 2004
    Assignee: St. Jude Childrens Research Hospital
    Inventors: Mary K. Danks, Philip M. Potter, Peter J. Houghton
  • Combination therapy for cancer
    Publication number: 20030229112
    Abstract: A method for treating a human patient afflicted with cancer, is provided in which therapeutically effective amounts of temozolomide and irinotecan are administered to such a patient.
    Type: Application
    Filed: January 24, 2001
    Publication date: December 11, 2003
    Inventor: Peter J. Houghton
  • N-substituted phenoxazines for treating multidrug resistant cancer cells
    Patent number: 5371081
    Abstract: Disclosed are compounds useful in potentiating the cytotoxic effect of chemotherapeutic agents, the compounds having the formula: ##STR1## and pharmacologically acceptable salts thereof, wherein R is --H or --[C(O)].sub.a --(CH.sub.2).sub.b --A, a is 0-1 and b is 0-6 provided that a and b are not both zero; and A is selected from the group consisting of--NR.sub.1 R.sub.2 wherein R.sub.1 and R.sub.2 are independently alkyl having 1 to 4 carbon atoms, and either or both of R.sub.1 and R.sub.2 are optionally substituted with --OH; ##STR2## wherein X and Y are independently alkylene having 1 to 4 carbon atoms, and Z is --O--, --N(R.sub.3)--, or --CH(R.sub.4)--, wherein R.sub.3 and R.sub.4 are each hydrogen or alkyl having 1 to 4 carbon atoms optionally substituted with a hydroxyl group;halide; and trihalomethyl.
    Type: Grant
    Filed: September 24, 1993
    Date of Patent: December 6, 1994
    Assignee: St. Jude Children's Research Hospital
    Inventors: Peter J. Houghton, Julie K. Horton, Kuntebommanahalli N. Thimmaiah